Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057239 · ClinicalTrials.gov registry record · Phase 2
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 546
- Enrollment target
NCT00057239: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00057239 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 546 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (311% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057239, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 546 participants
- Enrollment target
Study Summary
A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)
Interventions
- DRUG Radafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 546 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
What the finished NCT00057239 record still lists
NCT00057239 is an interventional study that assigns participants to a tested intervention. The registered 546 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (311% higher).
The record links to 0 conditions, and to 1 intervention - of which Radafaxine is the first listed.
NCT00057239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00057239 about?
NCT00057239 is a clinical study titled "An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder". A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)
What is the current status of trial NCT00057239?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 546 participants. The study started on 2003-03. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00057239?
The interventions under investigation include: Radafaxine (DRUG).
Who is sponsoring clinical trial NCT00057239?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00057239's enrollment target sits among peer trials
546 62nd of 2000 higher than 1,939 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
- NCT06850922 · 546 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia